We design and operate patient-centered health record registries for pharma and biotech. Your RWE budget funds the study. We build the patient portal infrastructure — and the consented longitudinal dataset compounds in value long after the study closes.
Pharma funds the build.
The research services contract covers platform development. The data asset — consented patient cohort, longitudinal PROs — remains after study close.
Patients are the customer, not the product.
Our portal gives patients genuine value — their full health record in one place. That ethical alignment drives higher enrollment and better data quality.
Enrolled through advocacy orgs, not ads.
We recruit through trusted patient communities. Pre-existing trust means faster enrollment, lower dropout, and richer longitudinal data.
End-to-end registry services — from protocol design through cohort reactivation. We handle the infrastructure so your team stays focused on the science.
End-to-end registry protocol design: research question framing, IRB submission, consent framework, data collection plan, and steering committee governance structure.
HIPAA-compliant patient portal with SMART on FHIR EHR integration — aggregating records from 90%+ of US health systems. Built for the study, owned as a platform asset.
Longitudinal patient-reported outcomes: symptoms, quality of life, medication adherence, and care experience — primary data no claims or EMR database can replicate.
Patient recruitment through established patient advocacy organization partnerships — condition-specific communities with pre-existing trust that accelerates enrollment and retention.
Primary analysis, manuscript preparation, and conference submission. Co-authorship with pharma sponsor and external steering committee for maximum scientific credibility.
After study close, the enrolled cohort remains active. Pre-screen patients for trial eligibility, offer longitudinal follow-up to new sponsors, or expand to adjacent indications.
Most registry vendors build the data collection layer and stop. We build the platform, run the study, recruit through advocacy partners, and hand you a consented longitudinal cohort that keeps compounding in value. That is a different business model — and a different evidence asset.